BlackRock
MLTX icon

BlackRock’s MoonLake Immunotherapeutics MLTX Stock Holding History

BlackRock’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.3M Buy
1,094,791
+72,940
+7% +$1.32M ﹤0.01% 3212
2026
Q1 		$19M Buy
1,021,851
+735,258
+257% +$12.2M ﹤0.01% 3114
2025
Q4 		$3.78M Buy
286,593
+161,212
+129% +$1.9M ﹤0.01% 3930
2025
Q3 		$899K Sell
125,381
-201,961
-62% -$10.5M ﹤0.01% 4312
2025
Q2 		$15.5M Buy
327,342
+41,133
+14% +$1.68M ﹤0.01% 3164
2025
Q1 		$11.2M Sell
286,209
-82,636
-22% -$3.56M ﹤0.01% 3262
2024
Q4 		$20M Sell
368,845
-31,940
-8% -$1.63M ﹤0.01% 3059
2024
Q3 		$20.2M Buy
400,785
+8,761
+2% +$411K ﹤0.01% 3037
2024
Q2 		$17.2M Sell
392,024
-16,256
-4% -$689K ﹤0.01% 3071
2024
Q1 		$20.5M Buy
408,280
+26,554
+7% +$1.44M ﹤0.01% 2985
2023
Q4 		$23.1M Sell
381,726
-367,152
-49% -$18.9M ﹤0.01% 2934
2023
Q3 		$42.7M Buy
748,878
+91,344
+14% +$5.04M ﹤0.01% 2491
2023
Q2 		$33.5M Buy
657,534
+542,604
+472% +$14.6M ﹤0.01% 2724
2023
Q1 		$2.46M Sell
114,930
-626,828
-85% -$10.5M ﹤0.01% 3955
2022
Q4 		$7.79M Sell
741,758
-74
-0% -$658 ﹤0.01% 3507
2022
Q3 		$5.76M Sell
741,832
-74
-0% -$523 ﹤0.01% 3694
2022
Q2 		$3.9M Hold
741,906
– – ﹤0.01% 3936
2022
Q1 		$8.24M Hold
741,906
– – ﹤0.01% 3683
2021
Q4 		$7.34M Sell
741,906
-5,957
-0.8% -$59.2K ﹤0.01% 3833
2021
Q3 		$7.37M Hold
747,863
– – ﹤0.01% 3809
2021
Q2 		$7.74M Sell
747,863
-2,290
-0.3% -$23.3K ﹤0.01% 3737
2021
Q1 		$7.66M Hold
750,153
– – ﹤0.01% 3726
2020
Q4 		$8.53M Buy
+750,153
New +$7.96M ﹤0.01% 3450

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BlackRock's MLTX Position: Q2 2026 in Review

BlackRock increased its MoonLake Immunotherapeutics (MLTX) stake by 7.1% in Q2 2026, buying an estimated $1.32M and bringing the position to 1,094,791 shares worth $21.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3212.

BlackRock first reported a position in MLTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $42.7M in Q3 2023. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • BlackRock held 1,094,791 shares of MoonLake Immunotherapeutics worth $21.3M as of Q2 2026.
  • BlackRock bought 72,940 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.32M.
  • MoonLake Immunotherapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3212 holding.
  • BlackRock first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 23 quarters since.
  • BlackRock's MoonLake Immunotherapeutics position peaked at $42.7M in Q3 2023.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.